Bliss GVS Pharma Limited — Board Meeting, 24-10-2024: Outcome of Board Meeting

The Company’s Board of Directors approved the unaudited financial results for Q2 2024, appointed Mr. Nandkumar Kashinath Chodankar as the new Chairman, and announced management changes due to internal reporting adjustments. Additionally, the Company paid fines imposed by BSE and NSE for non-compliance related to Mr. Chodankar's prior appointment, clarifying its regulatory commitment and intention to appeal if necessary. Details of the fine and management changes are attached.